JP2024532810A - 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 - Google Patents

免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2024532810A
JP2024532810A JP2024508786A JP2024508786A JP2024532810A JP 2024532810 A JP2024532810 A JP 2024532810A JP 2024508786 A JP2024508786 A JP 2024508786A JP 2024508786 A JP2024508786 A JP 2024508786A JP 2024532810 A JP2024532810 A JP 2024532810A
Authority
JP
Japan
Prior art keywords
antigen
compound
subject
composition
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532810A5 (cg-RX-API-DMAC7.html
Inventor
アナス エム. ファタラー,
スコット ディー. ラーセン,
アブドゥルラウフ ラマダン,
Original Assignee
ラピックス セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラピックス セラピューティクス, インコーポレイテッド filed Critical ラピックス セラピューティクス, インコーポレイテッド
Publication of JP2024532810A publication Critical patent/JP2024532810A/ja
Publication of JP2024532810A5 publication Critical patent/JP2024532810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024508786A 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 Pending JP2024532810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233163P 2021-08-13 2021-08-13
US63/233,163 2021-08-13
PCT/US2022/074903 WO2023019242A1 (en) 2021-08-13 2022-08-12 Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Publications (2)

Publication Number Publication Date
JP2024532810A true JP2024532810A (ja) 2024-09-10
JP2024532810A5 JP2024532810A5 (cg-RX-API-DMAC7.html) 2025-08-19

Family

ID=83192025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508786A Pending JP2024532810A (ja) 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US20240351977A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384495A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532810A (cg-RX-API-DMAC7.html)
KR (1) KR20240046744A (cg-RX-API-DMAC7.html)
CN (1) CN118076582A (cg-RX-API-DMAC7.html)
CA (1) CA3228238A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023019242A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12697320B2 (en) 2021-01-29 2026-08-04 Tim Therapeutics, Inc. Tartaric acid analogs and uses thereof
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
US20260144239A1 (en) 2022-10-25 2026-05-28 Lapix Therapeutics, Inc. Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509968A (ja) * 2012-03-14 2015-04-02 バイオニア・アクティーゼルスカブBioneer A/S 全血中のヒトcd14+単球を特異的に標的化するためのカチオン性リポソーム薬物送達系
JP2016531853A (ja) * 2013-09-24 2016-10-13 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 抗原特異的免疫原性を低減するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859284B2 (en) * 2009-10-22 2014-10-14 The United States Of America, As Represented By The Secretary Of The Navy Delivery of nanoparticles to neurons
ES2952038T3 (es) * 2016-04-05 2023-10-26 Univ New York State Res Found Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune
US20240173389A1 (en) * 2021-03-11 2024-05-30 Lapix Therapeutics, Inc. Compositions and Methods For Reducing Immune Intolerance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509968A (ja) * 2012-03-14 2015-04-02 バイオニア・アクティーゼルスカブBioneer A/S 全血中のヒトcd14+単球を特異的に標的化するためのカチオン性リポソーム薬物送達系
JP2016531853A (ja) * 2013-09-24 2016-10-13 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 抗原特異的免疫原性を低減するための組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"REGISTRY(STN)[online]", CAS登録番号 2278025-97-9等, JPN7026002309, 4 March 2019 (2019-03-04), ISSN: 0005871003 *

Also Published As

Publication number Publication date
WO2023019242A9 (en) 2023-04-20
CA3228238A1 (en) 2023-02-16
KR20240046744A (ko) 2024-04-09
WO2023019242A1 (en) 2023-02-16
EP4384495A1 (en) 2024-06-19
US20240351977A1 (en) 2024-10-24
CN118076582A (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
US20240351977A1 (en) Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders
US20240173389A1 (en) Compositions and Methods For Reducing Immune Intolerance
JP7189021B2 (ja) 医療において使用するための、免疫チェックポイントモジュレータと、細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む複合体との組合せ
JP7804370B2 (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
RU2579659C2 (ru) Способ для применения в терапии
CN115103689A (zh) 用于药物递送的树枝状大分子组合物和方法
JP7719072B2 (ja) 三分岐n-アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
WO2016050208A1 (zh) 一种多官能化聚乙二醇衍生物修饰的生物相关物质
US20220280557A1 (en) Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders
WO2022083694A1 (zh) 叶酸和叶酸修饰在诱导B细胞免疫耐受和靶向mIgM阳性表达的B细胞淋巴瘤中的用途
US10030067B2 (en) Compounds for treating neurodegenerative proteinopathies
US20110123566A1 (en) Endogenous adjuvant molecules and uses thereof
JP2023525758A (ja) Akt3モジュレーターおよびその使用方法
US20220226499A1 (en) Metabolite Delivery for Modulating Metabolic Pathways of Cells
ES2993108T3 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
WO2024118602A1 (en) Compositions and methods for reducing immune intolerance and treating autoimmune disorders
US20250066420A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
CN107407673B (zh) 新颖聚醣结合物及其使用方法
HK40081468A (en) Dendrimer compositions and methods for drug delivery
CN107407673A (zh) 新颖聚醣结合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260527

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260629